New advances in the clinical management of RAS and BRAF mutant colorectal cancer patients.

doi:10.1080/17474124.2021.1826305

Back to search

Article

New advances in the clinical management of RAS and BRAF mutant colorectal cancer patients.

Expert review of gastroenterology & hepatology - 1 Jan 2021

Ruffinelli Jose Carlos, Santos Vivas Cristina, Sanz-Pamplona Rebeca, Moreno Victor

Abstract excerpt

INTRODUCTION: In colorectal carcinogenesis, genetic alterations in RAS and BRAF oncogenes play an important role for cancer initiation and/or progression and represent a key focus in the search for targeted therapies. Despite many years of research and a great amount of studies, until very recent...

Topics

Biomarkers, Tumor
Colorectal Neoplasms
Genes, ras
Humans
Mitogen-Activated Protein Kinase Kinases
Mutation
Oncogenes
Protein Kinase Inhibitors
Proto-Oncogene Proteins B-raf

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.